We have developed a unique series of untargeted platforms (to cover the physicochemical and biochemical space of metabolites) and targeted biology-driven platforms (to cover specific metabolites present at ultra-low concentrations and/or requiring specialised sample pre-treatment). Our current metabolomics methods can detect >2000 metabolites and lipids; half of these compounds are identified, and 25% are reported in absolute concentrations. For example, we are interested to better study modified fatty acids and lipids.

 

We are miniaturizing our platforms using nanoLC-MS and improving the injection into CE-MS and the interfacing of CE and MS.